Gelteq (GELS) Registration filing summary

Company overview and business model

• Develops and commercializes white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports, and OTC products, focusing on out-licensing technology and manufacturing under license.

• Product suite leverages patent-pending multiple-ingredient dosage forms, with applications in both human and animal health.

• Business model centers on licensing, partnerships, and white/private label manufacturing, targeting high-margin, low-competition markets such as pet health and nutraceuticals.

• Holds a portfolio of granted and pending patents and trademarks across multiple jurisdictions, with ongoing R&D and IP expansion.

• Operations are supported by partnerships with leading research institutions and contract manufacturers in Australia, China, and the US.

Financial performance and metrics

• Revenue from contracts with customers was AUD $79,843 for FY2023, down from AUD $147,536 in FY2022; no revenue recognized for the nine months ended March 31, 2024.

• Net losses were AUD $3,506,220 in FY2023 and AUD $3,368,891 in FY2022; loss for the nine months ended March 31, 2024 was AUD $2,413,063.

• Cash and cash equivalents were AUD $145,861 as of March 31, 2024, with current liabilities exceeding current assets by AUD $2,987,496.

• Deferred revenue as of March 31, 2024 was AUD $125,359, reflecting undelivered orders due to customer cash flow issues.

• Intangible assets (mainly trade secrets and patents) comprise over 96% of total assets, with no impairment recognized as of March 31, 2024.

Use of proceeds and capital allocation

• Net proceeds of approximately USD $5.38 million from the IPO will be allocated to IP protection, R&D, regulatory work, sales and marketing, manufacturing capacity, and general corporate purposes.

• Capital will also support working capital needs and potential acquisitions or investments in synergistic businesses.